Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981048 | 0.88 | TP53 (0.33) | EGFRTP53ALDH1A1 | |
| SCHEMBL978639 | 0.83 | KDM1A (0.37) | EGFRTP53PTGDR2 | |
| SCHEMBL981322 | 0.78 | EGFR (0.34) | EGFRTP53 | |
| SCHEMBL979774 | 0.74 | ACACB (0.34) | EGFRPTGDR2BRD4 | |
| SCHEMBL983502 | 0.73 | PTGDR2 (0.31) | PTGDR2 | |
| SCHEMBL979169 | 0.71 | KDM1A (0.36) | EGFRTP53PTGDR2 | |
| SCHEMBL981482 | 0.67 | TP53 (0.33) | EGFRTP53ALDH1A1 | |
| SCHEMBL981146 | 0.66 | KDR (0.32) | EGFRPTGDR2 | |
| SCHEMBL980982 | 0.65 | TP53 (0.30) | TP53 | |
| SCHEMBL978620 | 0.65 | TP53 (0.34) | TP53PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456765-B1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-8334287-B2 | Imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2456765-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011006910-A1 | IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015202-A1 | IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015202-A1 | IMIDAZOLES | GRM5, GRM1, GRIK5 | EGFR 486/4885TP53 4689/4885PTGDR2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.